{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49,
    65,
    66,
    67,
    68,
    69,
    70,
    71,
    72,
    73,
    95
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "First administration of investigational product",
        "anchorType": "FirstDose",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 60,
        "sourceText": "Day 1 \nTreatment",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_llm_1",
        "definition": "Study entry and the start of symptom assessment",
        "anchorType": "Day1",
        "classification": "Visit",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 80,
        "sourceText": "at study entry (‘Day 1’ symptom count starts from the first day of symptoms), plus the presence of select symptoms within 24 hours prior to Day 1.",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_2",
        "definition": "Screening visit",
        "anchorType": "Screening",
        "classification": "Visit",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 20,
        "sourceText": "Screening \n \nDay",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_3",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 10,
        "sourceText": "informed consent",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_4",
        "definition": "Procedure",
        "anchorType": "Custom",
        "classification": "Conceptual",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 100,
        "sourceText": "Procedure",
        "encounterId": null,
        "activityId": null
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "every day"
      },
      {
        "id": "rep_daily_3",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "sourceText": "Follow-up Period"
      },
      {
        "id": "rep_window_4",
        "type": "Continuous",
        "sourceText": "4 hours post"
      },
      {
        "id": "rep_window_5",
        "type": "Continuous",
        "sourceText": "24 hours after"
      },
      {
        "id": "rep_window_6",
        "type": "Continuous",
        "sourceText": "2 hours post"
      },
      {
        "id": "rep_window_8",
        "type": "Continuous",
        "sourceText": "4 days after"
      },
      {
        "id": "rep_window_21",
        "type": "Continuous",
        "sourceText": "30 days after"
      },
      {
        "id": "rep_llm_1",
        "type": "Daily",
        "startOffset": "P1D",
        "endOffset": "P29D",
        "interval": "P1D",
        "minObservations": 29,
        "exitCondition": "Completion of Day 29",
        "sourceText": "Participant-reported symptom diary Daily through Day 29"
      },
      {
        "id": "rep_llm_2",
        "type": "Daily",
        "startOffset": "P1D",
        "endOffset": "P29D",
        "interval": "P1D",
        "minObservations": 29,
        "exitCondition": "Completion of Day 29",
        "sourceText": "Participant-reported symptom reminder Daily through Day 29"
      },
      {
        "id": "rep_llm_3",
        "type": "Daily",
        "startOffset": "P1D",
        "endOffset": "P4D",
        "interval": "P1D",
        "minObservations": 4,
        "exitCondition": "Completion of first 4 days after IMP administration",
        "sourceText": "the sentinel group will be contacted daily (in-person or by telephone) for the first 4 days after IMP administration"
      },
      {
        "id": "rep_llm_4",
        "type": "Daily",
        "startOffset": "P1D",
        "endOffset": "P1D",
        "interval": "P1D",
        "minObservations": 1,
        "exitCondition": "Completion of Day 1 safety monitoring",
        "sourceText": "Telephone contact for safety monitoring Daily"
      },
      {
        "id": "rep_llm_5",
        "type": "Interval",
        "startOffset": "P0D",
        "endOffset": "P1D",
        "interval": "PT24H",
        "minObservations": 2,
        "exitCondition": "Dosing of second participant in sentinel group",
        "sourceText": "At each site, there will be an interval of 24 hours after dosing of the first participant in the sentinel group before the next participant can be dosed."
      },
      {
        "id": "rep_llm_6",
        "type": "Continuous",
        "startOffset": "-P7D",
        "endOffset": "P1D",
        "interval": "P7D",
        "minObservations": 1,
        "exitCondition": "IMP administration",
        "sourceText": "Following screening, and no more than 7 days (‘Day 1’ symptom count starts from the first day of symptoms) from self-reported onset of COVID-19-related symptoms or measured fever, participants will receive a single dose of IMP."
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "TREATMENT",
          "INTENSIVE_FOLLOW_UP",
          "LIMITED_FOLLOW_UP",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Day 366",
          "Day 29",
          "Day 3",
          "Screening",
          "Day 15",
          "Day 6",
          "Day 8",
          "Day 85",
          "Day 169",
          "Day 1",
          "Day 457",
          "End of Study"
        ],
        "sourceText": "[{'condition': 'Subject experiences AE or SAE', 'path': ['AE_REPORTING', 'FOLLOW_UP_UNTIL_RESOLUTION']}, {'condition': 'Early Termination or Withdrawal', 'path': ['EARLY_DISCONTINUATION_VISIT']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Serum Sample",
        "executionType": "Single",
        "rationale": "SINGLE signals: 5"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Recurring",
        "rationale": "RECURRING signals: 2"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Adverse Events",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Concomitant Medications",
        "executionType": "Single",
        "rationale": "SINGLE signals: 5"
      },
      {
        "activityId": "Laboratory Assessments",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Dosing",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Diary",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Screening Assessment",
        "executionType": "Single",
        "rationale": "Initial evaluation to determine eligibility performed only once at the start of the study."
      },
      {
        "activityId": "Primary Endpoint Event Monitoring",
        "executionType": "Single",
        "rationale": "Continuous monitoring for events until the data cut-off of 30 days after 43 events are confirmed."
      },
      {
        "activityId": "Symptom Onset Assessment",
        "executionType": "Single",
        "rationale": "Determination of the specific date of symptom onset used to define the early intervention analysis set."
      },
      {
        "activityId": "Baseline Seronegative Testing",
        "executionType": "Single",
        "rationale": "One-time assessment at baseline to define the seronegative analysis set."
      },
      {
        "activityId": "Schedule of Activities Assessments",
        "executionType": "Single",
        "rationale": "Standard clinical trial assessments performed at scheduled study visits as indicated in the Schedule of Activities."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "general",
        "text": "a. Visits noted P/H can be performed either in-person at clinical site or at home depending on the participant's clinical status, availability of safe transfer to sites (eg, to avoid risk of infection spread), and local guidelines for travel restrictions/social distancing. For home visits, a nurse or HCP trained on study procedures will visit the participant at home; nasal swabs, blood collection (where at-home collection is possible), and inspection of injection sites will be performed by the nurse or HCP. Nurse or HCP will ensure shipment of specimens collected and reporting of AEs to study sites.",
        "footnoteId": "fn_1",
        "structuredCondition": "location.choice(in-person, home) IF (participant_status == 'unstable' OR travel_restricted == true)",
        "appliesToActivityIds": [
          "nasal swabs",
          "blood collection",
          "inspection of injection sites"
        ],
        "sourceText": "a. Visits noted P/H can be performed either in-person at clinical site or at home depending on the p"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "general",
        "text": "b. Perform if no documentation of SARS-CoV-2 infection available; tested locally.",
        "footnoteId": "fn_2",
        "structuredCondition": "procedure.required IF (documentation_sars_cov2 == false)",
        "appliesToActivityIds": [
          "SARS-CoV-2 testing"
        ],
        "sourceText": "b. Perform if no documentation of SARS-CoV-2 infection available; tested locally."
      },
      {
        "id": "fn_cond_3",
        "conditionType": "general",
        "text": "c. Assessment will be performed only for participants attending in-person visits, or if a nurse or HCP visiting the participant at home is properly trained for these assessments.",
        "footnoteId": "fn_3",
        "structuredCondition": "procedure.required IF (visit_type == 'in-person' OR staff_trained == true)",
        "appliesToActivityIds": [
          "Assessment"
        ],
        "sourceText": "c. Assessment will be performed only for participants attending in-person visits, or if a nurse or H"
      },
      {
        "id": "fn_cond_4",
        "conditionType": "general",
        "text": "d. Height is recorded only at the screening visit.",
        "footnoteId": "fn_4",
        "structuredCondition": "frequency.once(screening)",
        "appliesToActivityIds": [
          "Height"
        ],
        "sourceText": "d. Height is recorded only at the screening visit."
      },
      {
        "id": "fn_cond_5",
        "conditionType": "timing_after",
        "text": "e. Perform pre-dose and 15 minutes (± 5 minutes) after both injections are complete.",
        "footnoteId": "fn_5",
        "structuredCondition": "timing.pre_dose AND timing.post_dose(PT15M, window=PT5M)",
        "appliesToActivityIds": [
          "Assessment"
        ],
        "timingConstraint": "PT15M",
        "sourceText": "e. Perform pre-dose and 15 minutes (± 5 minutes) after both injections are complete."
      },
      {
        "id": "fn_cond_6",
        "conditionType": "timing_at",
        "text": "f. Perform pre-dose on Day 1.",
        "footnoteId": "fn_6",
        "structuredCondition": "timing.pre_dose(Day 1)",
        "appliesToActivityIds": [
          "Assessment"
        ],
        "sourceText": "f. Perform pre-dose on Day 1."
      },
      {
        "id": "fn_cond_7",
        "conditionType": "timing_before",
        "text": "h. Urine pregnancy test (local laboratory) at screening. Perform another urine test (local laboratory) on Day 1 if screening urine test was performed on Day -1. Single serum (central laboratory) must be performed on Day 1. Sample urine test must return negative result before dosing.",
        "footnoteId": "fn_8",
        "structuredCondition": "timing.pre_dose(Day 1) IF (result_urine_pregnancy == 'negative')",
        "appliesToActivityIds": [
          "Dosing",
          "Urine pregnancy test",
          "Serum pregnancy test"
        ],
        "sourceText": "h. Urine pregnancy test (local laboratory) at screening. Perform another urine test (local laborator"
      },
      {
        "id": "fn_cond_8",
        "conditionType": "general",
        "text": "i. Urine pregnancy test (local laboratory).",
        "footnoteId": "fn_9",
        "sourceText": "i. Urine pregnancy test (local laboratory)."
      },
      {
        "id": "fn_cond_9",
        "conditionType": "timing_at",
        "text": "j. Participants will report COVID-19-related symptoms daily in an electronic device, starting pre-dose and post-dose on Day 1.",
        "footnoteId": "fn_10",
        "structuredCondition": "frequency.daily(START=Day 1 pre-dose)",
        "appliesToActivityIds": [
          "COVID-19-related symptoms reporting"
        ],
        "sourceText": "j. Participants will report COVID-19-related symptoms daily in an electronic device, starting pre-do"
      },
      {
        "id": "fn_cond_10",
        "conditionType": "frequency_daily",
        "text": "k. Participant will be reminded every day through Day 29 to complete their diary. This reminder will be received through the electronic device.",
        "footnoteId": "fn_11",
        "structuredCondition": "frequency.daily(UNTIL=Day 29)",
        "appliesToActivityIds": [
          "Diary reminder"
        ],
        "sourceText": "k. Participant will be reminded every day through Day 29 to complete their diary. This reminder will"
      },
      {
        "id": "fn_cond_11",
        "conditionType": "frequency_daily",
        "text": "l. If Day 29 visit is conducted earlier in ± 4 day window, participant should retain symptom diary in order to complete required daily entries through Study Day 29.",
        "footnoteId": "fn_12",
        "structuredCondition": "timing.continue(UNTIL=Day 29) IF (visit_day < 29)",
        "appliesToActivityIds": [
          "Symptom diary"
        ],
        "sourceText": "l. If Day 29 visit is conducted earlier in ± 4 day window, participant should retain symptom diary i"
      },
      {
        "id": "fn_cond_12",
        "conditionType": "general",
        "text": "m. Mid-turbinate nasal swab is tested centrally. Sequencing applies to nasal swabs collected through Day 15.",
        "footnoteId": "fn_13",
        "structuredCondition": "procedure.required IF (timing.current <= Day 15)",
        "appliesToActivityIds": [
          "Sequencing"
        ],
        "sourceText": "m. Mid-turbinate nasal swab is tested centrally. Sequencing applies to nasal swabs collected through"
      },
      {
        "id": "fn_cond_13",
        "conditionType": "timing_before",
        "text": "n. Pre-dose sample and post-dose sample (ie, samples obtained prior to and upon completion of IMP administered via IM injections on Day 1).",
        "footnoteId": "fn_14",
        "sourceText": "n. Pre-dose sample and post-dose sample (ie, samples obtained prior to and upon completion of IMP ad"
      },
      {
        "id": "fn_cond_14",
        "conditionType": "general",
        "text": "o. Serum vitamin D, serum zinc, dependent on availability of laboratory kits.",
        "footnoteId": "fn_15",
        "structuredCondition": "procedure.required IF (lab_kits_available == true)",
        "appliesToActivityIds": [
          "Serum vitamin D",
          "Serum zinc"
        ],
        "sourceText": "o. Serum vitamin D, serum zinc, dependent on availability of laboratory kits."
      },
      {
        "id": "fn_cond_15",
        "conditionType": "timing_before",
        "text": "p. Perform 30 minutes (± 10 minutes) after the IMP has been administered and just prior to release from the study site or departure of the study staff.",
        "footnoteId": "fn_16",
        "structuredCondition": "timing.post_dose(PT30M, window=PT10M) AND timing.before(release)",
        "appliesToActivityIds": [
          "Assessment"
        ],
        "timingConstraint": "PT30M",
        "sourceText": "p. Perform 30 minutes (± 10 minutes) after the IMP has been administered and just prior to release f"
      },
      {
        "id": "fn_cond_16",
        "conditionType": "timing_recurring",
        "text": "q. If evidence of injection site reaction persists at the Day 6 visit, the injection site will be rechecked at each visit until no evidence of an active reaction remains.",
        "footnoteId": "fn_17",
        "structuredCondition": "frequency.every_visit UNTIL (injection_site_reaction == false)",
        "appliesToActivityIds": [
          "Injection site recheck"
        ],
        "sourceText": "q. If evidence of injection site reaction persists at the Day 6 visit, the injection site will be re"
      },
      {
        "id": "fn_cond_17",
        "conditionType": "timing_before",
        "text": "r. The first 20 participants dosed (ie, the sentinel group) will undergo safety monitoring for 4 hours post IMP administration before further participants are dosed. At each site, there will be an interval of 24 hours after dosing of the first participant in the sentinel group before the next participant can be dosed. The next 80 participants (21 to 100) will then undergo safety monitoring for 2 hours post IMP administration, otherwise the minimum safety monitoring time will be 1 hour. In addition, the sentinel group will be contacted daily (in-person or by telephone) for the first 4 days after IMP administration. Contact will be made by telephone on days when there is not an in-person visit.",
        "footnoteId": "fn_18",
        "structuredCondition": "timing.after(dosing of the first participant in the sentinel group before the next participant can be dosed. the next 80 participants (21 to 100) will then undergo safety monitoring for 2 hours post imp administration, otherwise the minimum safety monitoring time will be 1 hour. in addition, the sentinel group will be contacted daily (in-person or by telephone) for the first 4 days after imp administration. contact will be made by telephone on days when there is not an in-person visit., PT24M)",
        "appliesToActivityIds": [
          "Safety monitoring",
          "Sentinel group contact"
        ],
        "timingConstraint": "PT4H",
        "sourceText": "r. The first 20 participants dosed (ie, the sentinel group) will undergo safety monitoring for 4 hou"
      },
      {
        "id": "fn_cond_18",
        "conditionType": "timing_at",
        "text": "s. At Day 457 AE/SAE/AESI assessment will be made by telephone only.",
        "footnoteId": "fn_19",
        "structuredCondition": "visit_method.telephone IF (timing.current == Day 457)",
        "appliesToActivityIds": [
          "AE/SAE/AESI assessment"
        ],
        "sourceText": "s. At Day 457 AE/SAE/AESI assessment will be made by telephone only."
      },
      {
        "id": "fn_cond_19",
        "conditionType": "general",
        "text": "t. Note: Remote (denoted by R) visit: either a phone call, or a web-based virtual assessment.",
        "footnoteId": "fn_20",
        "sourceText": "t. Note: Remote (denoted by R) visit: either a phone call, or a web-based virtual assessment."
      },
      {
        "id": "fn_cond_20",
        "conditionType": "general",
        "text": "u. Note: Day 6 and Day 8 assessments must be performed on different days.",
        "footnoteId": "fn_21",
        "structuredCondition": "timing.distinct_days(Day 6, Day 8)",
        "appliesToActivityIds": [
          "Day 6 assessments",
          "Day 8 assessments"
        ],
        "sourceText": "u. Note: Day 6 and Day 8 assessments must be performed on different days."
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: Severe COVID-19 or Death from any cause",
        "endpointType": "Primary",
        "inputs": [
          "fever",
          "cough",
          "tachypnea",
          "dyspnea",
          "lung infiltrates",
          "SpO2",
          "respiratory distress",
          "WHO Clinical Progression Scale score",
          "vital status",
          "IMP_administration_date"
        ],
        "timeWindow": {
          "reference": "Day 1 (IMP administration)",
          "duration": "P28D"
        },
        "algorithm": "IF (death = TRUE) OR ((pneumonia = TRUE OR hypoxemia = TRUE) AND WHO_score >= 5) THEN 'Event' ELSE 'No Event'",
        "successCriteria": "A participant is classified as having the endpoint if they experience severe COVID-19 or death from any cause through Day 29.",
        "sourceText": "The primary efficacy endpoint is a composite of either severe COVID-19 or death from any cause through Day 29. Severe COVID-19 is characterized by a minimum of either pneumonia (fever, cough, tachypne"
      },
      {
        "id": "ep_2",
        "name": "Relative Risk Reduction (RRR)",
        "endpointType": "Primary",
        "inputs": [
          "incidence_AZD7442",
          "incidence_placebo"
        ],
        "timeWindow": {
          "reference": "Primary Analysis Data Cut-off",
          "duration": "30 days after 43 primary endpoint events"
        },
        "algorithm": "RRR = 1 - (Incidence in AZD7442 / Incidence in Placebo)",
        "successCriteria": "RRR not equal to zero (statistically significant difference between treatment groups).",
        "sourceText": "Efficacy will be calculated as the RRR, defined as 1-Relative Risk. The null hypothesis is that the RRR of severe COVID-19 or death from any cause through Day 29 in participants on AZD7442 compared wi"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Key Secondary Composite Endpoint",
        "variableType": "Composite",
        "sourceVariables": [
          "Death from any cause",
          "Hospitalization for COVID-19 complications or sequelae"
        ],
        "derivationRule": "Binary indicator (Yes/No) if either death from any cause OR hospitalization for COVID-19 complications/sequelae occurs",
        "baselineDefinition": "Post-dose period starting from Day 1",
        "baselineVisit": "Day 1",
        "analysisWindow": "Day 1 to Day 169",
        "imputationRule": "Not specified in text",
        "unit": "Binary"
      },
      {
        "id": "dv_2",
        "name": "Relative Risk Reduction (RRR) of Key Secondary Endpoint",
        "variableType": "Custom",
        "sourceVariables": [
          "Key Secondary Composite Endpoint",
          "Treatment Group"
        ],
        "derivationRule": "Calculated based on the proportion of events in AZD7442 vs placebo at Day 169",
        "baselineDefinition": "Randomized treatment assignment",
        "baselineVisit": "Day 1",
        "analysisWindow": "Through Day 169",
        "imputationRule": "Not specified in text",
        "unit": "%"
      },
      {
        "id": "dv_3",
        "name": "Time to death or first hospitalization",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of Death",
          "Date of Hospitalization",
          "Date of IMP administration"
        ],
        "derivationRule": "Min(Date of Death, Date of first Hospitalization) - Date of IMP administration",
        "baselineDefinition": "Day 1 (Post-dose)",
        "baselineVisit": "Day 1",
        "analysisWindow": "Day 1 to Day 169",
        "imputationRule": "Kaplan-Meier censoring for participants without events",
        "unit": "Days"
      },
      {
        "id": "dv_4",
        "name": "Proportion of participants with respiratory failure",
        "variableType": "Categorical",
        "sourceVariables": [
          "Mechanical ventilation requirement",
          "ECMO requirement",
          "Non-invasive ventilation requirement",
          "High flow cannula oxygen delivery"
        ],
        "derivationRule": "Binary indicator (Yes/No) if any of the source requirements are met",
        "baselineDefinition": "Post-dose",
        "baselineVisit": "Day 1",
        "analysisWindow": "Through Day 29",
        "imputationRule": "Not specified in text",
        "unit": "Binary"
      },
      {
        "id": "dv_5",
        "name": "Progression of COVID-19-associated symptoms",
        "variableType": "Categorical",
        "sourceVariables": [
          "Participant-reported symptom diary entry"
        ],
        "derivationRule": "One or more symptoms progressing to a worse status than recorded in the diary entry prior to start of IMP",
        "baselineDefinition": "Symptom status recorded in diary prior to start of AZD7442 or placebo",
        "baselineVisit": "Pre-dose Day 1",
        "analysisWindow": "Through Day 29",
        "imputationRule": "Not specified in text",
        "unit": "Binary"
      },
      {
        "id": "dv_6",
        "name": "Undetectable SARS-CoV-2 over time",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "SARS-CoV-2 viral load"
        ],
        "derivationRule": "Time from Day 1 to the first instance where SARS-CoV-2 is undetectable",
        "baselineDefinition": "Baseline viral load status",
        "baselineVisit": "Day 1",
        "analysisWindow": "Through Day 29",
        "imputationRule": "Kaplan-Meier",
        "unit": "Days"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Treatment",
        "Intensive Follow Up",
        "Limited Follow Up",
        "End Of Study",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Treatment",
          "trigger": "Progress to Treatment"
        },
        {
          "fromState": "Treatment",
          "toState": "Intensive Follow Up",
          "trigger": "Progress to Intensive Follow Up"
        },
        {
          "fromState": "Intensive Follow Up",
          "toState": "Limited Follow Up",
          "trigger": "Progress to Limited Follow Up"
        },
        {
          "fromState": "Limited Follow Up",
          "toState": "End Of Study",
          "trigger": "Progress to End Of Study"
        },
        {
          "fromState": "Treatment",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "SCREENING",
        "Treatment": "TREATMENT",
        "Intensive Follow Up": "INTENSIVE_FOLLOW_UP",
        "Limited Follow Up": "LIMITED_FOLLOW_UP",
        "End Of Study": "END_OF_STUDY",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_llm_1",
        "treatmentName": "AZD7442",
        "frequency": "Single",
        "route": "IM",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 0.0,
            "unit": "",
            "description": "Investigational Medicinal Product (IMP)"
          }
        ],
        "durationDescription": "Single dose"
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Placebo",
        "frequency": "Single",
        "route": "IM",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 0.0,
            "unit": "",
            "description": "Matching placebo"
          }
        ],
        "durationDescription": "Single dose"
      }
    ],
    "visitWindows": [
      {
        "id": "visit_6",
        "visitName": "screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening",
        "sourceText": "Following screening, and no more than 7 days (‘Day 1’ symptom count starts from the first day of symptoms) from self-reported onset of COVID-19-related symptoms or measured fever, participants will re"
      },
      {
        "id": "visit_1",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "CONFIDENTIAL AND PROPRIETARY9 of 115 LIST OF TABLES"
      },
      {
        "id": "visit_12",
        "visitName": "End of Study",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 3,
        "sourceText": "End of Study Definition A participant is considered to have completed the study if he/she has completed all stages of the study, including the last scheduled procedure shown in the SoA (Table 1 for Co"
      },
      {
        "id": "visit_13",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "Increased supplemental oxygen requirement (only for participants on baseline supplemental oxygen) 5"
      },
      {
        "id": "visit_14",
        "visitName": "Visit 1",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "negative pregnancy test result at Visit 1 and during the study as in the SoA (Table 1 for Cohort 1 and Table 2 for Cohort 2)."
      },
      {
        "id": "visit_4",
        "visitName": "randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 6,
        "sourceText": "Persons aged 65 years and older at randomization x Persons aged < 65 years and having at least one of the following conditions:"
      },
      {
        "id": "visit_llm_3",
        "visitName": "Day 2 (Sentinel Group Only)",
        "targetDay": 2,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": false,
        "visitNumber": 3,
        "targetWeek": 1,
        "epoch": "Intensive Follow-up"
      },
      {
        "id": "visit_llm_4",
        "visitName": "Day 3 (Sentinel Group Only)",
        "targetDay": 3,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": false,
        "visitNumber": 4,
        "targetWeek": 1,
        "epoch": "Intensive Follow-up"
      },
      {
        "id": "visit_llm_5",
        "visitName": "Day 4 (Sentinel Group Only)",
        "targetDay": 4,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": false,
        "visitNumber": 5,
        "targetWeek": 1,
        "epoch": "Intensive Follow-up"
      },
      {
        "id": "visit_11",
        "visitName": "Day 6",
        "targetDay": 6,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 10,
        "sourceText": "If evidence of injection site reaction persists at the Day 6 visit, the injection site will be rechecked at each visit until no evidence of an active reaction remains. r The first 20 participants dose"
      },
      {
        "id": "visit_5",
        "visitName": "Day 8",
        "targetDay": 8,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 11,
        "epoch": "Intensive Follow-up",
        "sourceText": "group’s safety data through Day 8 has been reviewed by the DSMB in order to provide a recommendation to continue or to halt dosing of additional participants. Participants will be enrolled into one of"
      },
      {
        "id": "visit_10",
        "visitName": "Day 15",
        "targetDay": 15,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 12,
        "sourceText": "Mid-turbinate nasal swab is tested centrally. Sequencing applies to nasal swabs collected through Day 15. n Pre-dose sample and post-dose sample (ie, samples obtained prior to and upon completion of I"
      },
      {
        "id": "visit_8",
        "visitName": "Day 29",
        "targetDay": 29,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 13,
        "epoch": "Intensive Follow-up",
        "sourceText": "or death from any cause through Day 29. Severe COVID-19 is characterized by a minimum of either pneumonia (fever, cough, tachypnea, or dyspnea, AND lung infiltrates) or hypoxemia (SpO2 < 90% in room a"
      },
      {
        "id": "visit_15",
        "visitName": "Day 30",
        "targetDay": 30,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 14,
        "sourceText": "appropriate that they can discuss with the investigator and others after Day 30 so as to make an informed choice. The following considerations apply: x"
      },
      {
        "id": "visit_9",
        "visitName": "Day 169",
        "targetDay": 169,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 15,
        "sourceText": "events have been confirmed in the primary analysis population. A Day 169 analysis will be conducted when all participants have been followed through Day 169. A final analysis will be conducted when al"
      },
      {
        "id": "visit_3",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 16,
        "sourceText": "Follow-up, and Reporting ........................................................................... 82 Appendix C Handling of Human Biological Samples ................................................"
      },
      {
        "id": "visit_7",
        "visitName": "Day 457",
        "targetDay": 457,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 17,
        "epoch": "Limited Follow-up",
        "sourceText": "28 days of intensive follow-up, followed by limited follow-up through Day 457. Disclosure Statement: This is a parallel-group treatment study with 2 arms that are double-blind."
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "1:1",
      "method": "Stratified blocked randomization",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_llm_1",
          "name": "Time from symptom onset",
          "categories": [
            "≤ 5 days",
            "> 5 days"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_2",
          "name": "Risk of progression to severe COVID-19",
          "categories": [
            "High-risk",
            "Low-risk"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "Clinical Study Protocol - 7.0 \nAstraZeneca \nAZD7442 - D8851C00001 \n \nCONFIDENTIAL AND PROPRIETARY12 of 115 \n \nADA Anti-drug-antibody; AE Adverse event; AESI Adverse event of special interest; AUC Area"
    }
  }
}